Dedicated to women's medical care and cancer treatment with a focus on breast cancer treatment, Boekiyo has earned a reputation throughout Japan as a specialist breast cancer hospital. Based on the professionalism and quality of care cultivated for women's medical treatment, we promote a full range of treatment for women with a wider range of response capabilities.
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.
St. Marianna's Medical University Hospital is one of the top hospitals in Japan, specializing in breast surgery and other related diseases.
When it comes to the breath detector, everyone will think of the thing used by the traffic police to check drinking and driving. For those who drink and drive, they will lose their temper when they see the breath detector. In fact, the gas exhaled by the human body has many characteristics. It can not only detect alcohol, but also reflect the health of the human body and detect some diseases. This breath detector introduced in this article can detect breast cancer, diabetes, lung cancer, Parkinson's disease, asthma, schizophrenia, kidney and liver failure and other diseases.
It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.
The clinical trial (PARABLE) will take place at 22 sites across the UK and is planned to recruit 192 patients at higher risk of developing heart problems. the PARABLE trial is led by researchers from the Royal Marsden Hospital, the University of Cambridge, and the Institute of Cancer Research (ICR) UK, and is managed by the Clinical Trials and Statistics Unit, funded by Cancer Research UK, at the Institute of Cancer Research (ICR). was conducted.
The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.
In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.
More than half of all women will have a lump or nodule in their breast, but most lumps and nodules are not cancer
Every year, 40000 women die of breast cancer in the United States alone. When cancers are discovered at an early stage, they can often be cured. Mammography is the best alternative diagnostic method, but this method also has shortcomings. It often results in false positive results, leading to unnecessary surgery.
